Should I buy or sell Mineralys Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mineralys Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MLYS shares. View MLYS analyst ratings or view top-rated stocks .

What is Mineralys Therapeutics' stock price target for 2024?

3 brokers have issued twelve-month price targets for Mineralys Therapeutics' stock. Their MLYS share price targets range from $30.00 to $37.00. On average, they predict the company's share price to reach $33.50 in the next year. This suggests a possible upside of 211.6% from the stock's current price. View analysts price targets for MLYS or view top-rated stocks among Wall Street analysts .

How have MLYS shares performed in 2024?

Mineralys Therapeutics' stock was trading at $8.60 at the start of the year. Since then, MLYS shares have increased by 25.0% and is now trading at $10.75. View the best growth stocks for 2024 here .

When is Mineralys Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our MLYS earnings forecast .

How were Mineralys Therapeutics' earnings last quarter?

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) posted its quarterly earnings results on Thursday, March, 21st. The company reported ($0.61) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.24.

What ETF holds Mineralys Therapeutics' stock?

Virtus LifeSci Biotech Clinical Trials ETF holds 10,501 shares of MLYS stock, representing 1.22% of its portfolio.

When did Mineralys Therapeutics IPO?

Mineralys Therapeutics (MLYS) raised $180 million in an IPO on Friday, February 10th 2023. The company issued 12,000,000 shares at $14.00-$16.00 per share.

How do I buy shares of Mineralys Therapeutics?

Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MLYS

Mineralys Therapeutics (MLYS) Stock Price, News & Analysis

→ 2024's Must-Have Guide: Master Crypto Investment Today (From Darwin) (Ad)

Free MLYS Stock Alerts

$10.84

+0.09 (+0.84%)

(As of 10:38 AM ET)

Compare

Today's Range: $10.57
▼
$11.16
50-Day Range: $10.75
▼
$16.15
52-Week Range: $5.85
▼
$17.70

Volume: 19,793 shs
Average Volume: 160,179 shs
Market Capitalization: $537.99 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $33.50

Get Mineralys Therapeutics alerts:

Mineralys Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 211.6% Upside
$33.50 Price Target
Short Interest: Bearish
4.82% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$7.50 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.44) to ($3.34) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.40 out of 5 stars

Medical Sector

719th out of 918 stocks

Pharmaceutical Preparations Industry

331st out of 428 stocks

3.5

Analyst's Opinion

Consensus Rating
Mineralys Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Mineralys Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.82% of the float of Mineralys Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Mineralys Therapeutics has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in Mineralys Therapeutics has recently increased by 1.00%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Mineralys Therapeutics does not currently pay a dividend.
Dividend Growth
Mineralys Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MLYS.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Mineralys Therapeutics this week, compared to 1 article on an average week.
Search Interest
5 people have searched for MLYS on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Mineralys Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Mineralys Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,499,992.00 in company stock and sold $0.00 in company stock.
Percentage Held by Institutions
84.46% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Mineralys Therapeutics are expected to decrease in the coming year, from ($2.44) to ($3.34) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Mineralys Therapeutics is -5.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Mineralys Therapeutics is -5.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Mineralys Therapeutics has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Darwin

2024's Must-Have Guide: Master Crypto Investment Today

The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your crypto report

About Mineralys Therapeutics Stock (NASDAQ:MLYS)

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

MLYS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MLYS Stock News Headlines

April 2, 2024 | msn.com

Goldman starts Mineralys at buy, cites upcoming drug data

March 22, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Mineralys Therapeutics Amid Positive Clinical and Strategic Developments

April 19, 2024 | Darwin (Ad)

2024's Must-Have Guide: Master Crypto Investment Today

March 22, 2024 | finance.yahoo.com

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript

March 21, 2024 | msn.com

Mineralys Therapeutics files for $500M mixed shelf offering

March 21, 2024 | finance.yahoo.com

Mineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ...

March 21, 2024 | seekingalpha.com

Mineralys Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation

March 21, 2024 | globenewswire.com

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

April 19, 2024 | Darwin (Ad)

2024's Must-Have Guide: Master Crypto Investment Today

March 20, 2024 | finance.yahoo.com

MLYS Jun 2024 12.500 call

March 20, 2024 | finance.yahoo.com

MLYS Sep 2024 30.000 call

March 20, 2024 | benzinga.com

Mineralys Therapeutics Earnings Preview

March 18, 2024 | msn.com

Mineralys Therapeutics Set to Release Q4 and Full-Year 2023 Financial Results, Eyes on Future Growth Prospects

March 18, 2024 | seekingalpha.com

Mineralys Therapeutics: A Story To Keep An Eye On

March 16, 2024 | finance.yahoo.com

MLYS Apr 2024 15.000 call

March 16, 2024 | finance.yahoo.com

MLYS Mar 2024 20.000 call

March 13, 2024 | globenewswire.com

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024

March 4, 2024 | benzinga.com

Mineralys Therapeutics Stock (NASDAQ:MLYS) Dividends: History, Yield and Dates

February 9, 2024 | seekingalpha.com

Mineralys: 2nd Half 2024 Hypertension Data Readout

February 9, 2024 | bizjournals.com

Mineralys Therapeutics set to raise $120M from investors to develop treatment for high blood pressure

February 9, 2024 | msn.com

Mineralys Therapeutics Equity Sales: Investor Impact Report

February 9, 2024 | msn.com

Mineralys Therapeutics Announces Strategic Purchase Agreement

February 8, 2024 | msn.com

Mineralys Therapeutics stock jumps on $120M private placement financing

February 8, 2024 | finance.yahoo.com

Mineralys Therapeutics Announces $120 Million Private Placement Financing

January 29, 2024 | finance.yahoo.com

Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference

January 17, 2024 | finance.yahoo.com

Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know

January 6, 2024 | seekingalpha.com

MLYS Mineralys Therapeutics, Inc.

See More Headlines

Receive MLYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:MLYS
CUSIP: N/A
CIK: 1933414
Web: www.mineralystx.com
Phone: 888-378-6240
Fax: N/A
Employees: 28
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $33.50
High Stock Price Target: $37.00
Low Stock Price Target: $30.00
Potential Upside/Downside: +206.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.00)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-71,900,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -26.48%
Return on Assets: -25.52%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 23.76
Quick Ratio: 23.76

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.87 per share
Price / Book: 1.86

Miscellaneous

Outstanding Shares: 49,630,000
Free Float: N/A
Market Cap: $542.46 million
Optionable: Optionable
Beta: 2.35

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Jon Congleton (Age 61)
CEO & Director
Comp: $428.87k
Mr. Adam Scott Levy (Age 46)
CFO & Secretary
Comp: $409.17k
Dr. David M. Rodman M.D. (Age 69)
Chief Medical Officer
Comp: $423.66k
Dr. Brian Taylor Slingsby M.D. (Age 47)
M.P.H., Ph.D., Founder & Executive Chairman
Ms. Cindy Berejikian
Executive Vice President of Operations
Ms. Sarah Foster
Vice President of Human Resources
Dr. Robert McKean Ph.D.
Senior Vice President of CMC
Ms. Danielle Bradbury
Senior Vice President of Quality Assurance
Mr. Jeffrey N. Fellows
Senior Vice President of Regulatory Affairs
Ms. Jessica Ibbitson
Senior Vice President of Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MLYS Stock Analysis - Frequently Asked Questions

Should I buy or sell Mineralys Therapeutics stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mineralys Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MLYS shares.
View MLYS analyst ratings or view top-rated stocks.
What is Mineralys Therapeutics' stock price target for 2024?: 3 brokers have issued twelve-month price targets for Mineralys Therapeutics' stock. Their MLYS share price targets range from $30.00 to $37.00. On average, they predict the company's share price to reach $33.50 in the next year. This suggests a possible upside of 211.6% from the stock's current price.
View analysts price targets for MLYS or view top-rated stocks among Wall Street analysts.
How have MLYS shares performed in 2024?: Mineralys Therapeutics' stock was trading at $8.60 at the start of the year. Since then, MLYS shares have increased by 25.0% and is now trading at $10.75.
View the best growth stocks for 2024 here.
When is Mineralys Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our MLYS earnings forecast.

How were Mineralys Therapeutics' earnings last quarter?: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) posted its quarterly earnings results on Thursday, March, 21st. The company reported ($0.61) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.24.
What ETF holds Mineralys Therapeutics' stock?: Virtus LifeSci Biotech Clinical Trials ETF holds 10,501 shares of MLYS stock, representing 1.22% of its portfolio.
When did Mineralys Therapeutics IPO?: Mineralys Therapeutics (MLYS) raised $180 million in an IPO on Friday, February 10th 2023. The company issued 12,000,000 shares at $14.00-$16.00 per share.
How do I buy shares of Mineralys Therapeutics?: Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MLYS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Mineralys Therapeutics (MLYS) Stock Price, News & Analysis

Mineralys Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Mineralys Therapeutics Stock (NASDAQ:MLYS)

MLYS Stock Price History

MLYS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

MLYS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™